Zacks' Senior Life Sciences Analyst John Vandermosten initiates on AEON Biopharma with a $2.00 price target.
$AEON: Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar:
s27.q4cdn.com/906368049/fi...
#BiotechStocks #Biosimilars #Biologics #BotulinumToxin #ABP450 #MarketNews

Zymeworks has completed its acquisition of Theravance Biopharma, expanding its commercial portfolio through YUPELRI profit-share revenue and additional royalty assets.

#Biotech #BiotechStocks #Pharma

Disclaimer: This is NOT a financial advice

Oruka reports deeper Week 28 psoriasis responses for
ORKA-001 following two induction doses. The results come from a small Phase 2a trial.

#Biotech #BiotechStocks #ClinicalTrials #Phase2

Disclaimer: This is NOT a financial advice